NOAC for Patients with AF and ACS
International Journal of Arrhythmia
;
: 41-45, 2016.
Artigo
em Coreano
| WPRIM
| ID: wpr-70892
ABSTRACT
Atrial fibrillation (AF) can occur in acute coronary syndrome (ACS), which is a serious medical condition and may require the use of antiplatelet agents in addition to anticoagulants for stroke prevention. Recently, novel or non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly used for stroke prevention in patients with AF instead of traditional OACs. The duration of treatment or treatment with a stepwise approach (e.g. triple, double, or monotherapy) is determined depending on the clinical setting and the balance between the risks of ischemic stroke and bleeding. However, some concerns and controversies in the use of NOACs in patients with AF and ACS need to be addressed. Here, the current management for NOAC therapy in patients with ACS and AF will be reviewed based on recently published guidelines.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fibrilação Atrial
/
Inibidores da Agregação Plaquetária
/
Acidente Vascular Cerebral
/
Síndrome Coronariana Aguda
/
Hemorragia
/
Anticoagulantes
Tipo de estudo:
Guia de Prática Clínica
Limite:
Humanos
Idioma:
Coreano
Revista:
International Journal of Arrhythmia
Ano de publicação:
2016
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS